A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 03 May 2018 Status changed from not yet recruiting to recruiting.
- 07 Sep 2017 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.